NCT00336154

Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa

Randomised Double Blind Crossover Placebo Controlled Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Rambam Health Care Campus · Academic / Other
• Sex: All
• Age: 13 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Epidermolysis Bullosa(EB) is an inherited bullous disease. Tetracycline is believed to have anti inflammatory properties. 20 patients with EB older than 13 years will be treated for 4 months with tetracycline or placebo. After one month of wash out they will be treated for additional 4 m with placebo or tetracycline. The patients will be examined each month to estimate bulla formation,rate of healing .

Detailed description

Epidermolysis Bullosa(EB) is an inherited bullous disease. Tetracycline is believed to have anti inflammatory properties. 20 patients with EB older than 13 years will be treated for 4 months with tetracycline or placebo. After one month of wash out they will be treated for additional 4 m with placebo or tetracycline. The patients will be examined each month to estimate bulla formation,rate of healing .

Conditions

• Epidermolysis Bullosa

Interventions

Type	Name	Description
DRUG	tetracyclin

Timeline

• Primary completion: 2006-06-01
• First posted: 2006-06-13
• Last updated: 2020-10-28